Caribou Biosciences报告了关于同种异体CAR T疗法的临床数据，而Kyverna Therapeutics则推进了自身免疫项目Caribou Biosciences Reports Clinical Data on Allogeneic CAR T Therapies While Kyverna Therapeutics Advances Autoimmune Program

动脉网11-05

by GOAI由GOAI生成Share To分享到Caribou Biosciences has released clinical data on its allogeneic CAR T-cell therapies in two cancer indications, while Kyverna Therapeutics is preparing to advance its own CAR...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2581779056?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-11-05 16:03","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2581779056","market":"us","top_or_hot":-1,"title":"Caribou Biosciences报告了关于同种异体CAR T疗法的临床数据，而Kyverna Therapeutics则推进了自身免疫项目Caribou Biosciences Reports Clinical Data on Allogeneic CAR T Therapies While Kyverna Therapeutics Advances Autoimmune Program","media":"动脉网","content":"<div>\n<p>by GOAI由GOAI生成Share To分享到Caribou Biosciences has released clinical data on its allogeneic CAR T-cell therapies in two cancer indications, while Kyverna Therapeutics is preparing to advance its own CAR...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110516052697554e2c&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Caribou Biosciences报告了关于同种异体CAR T疗法的临床数据，而Kyverna Therapeutics则推进了自身免疫项目Caribou Biosciences Reports Clinical Data on Allogeneic CAR T Therapies While Kyverna Therapeutics Advances Autoimmune Program</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCaribou Biosciences报告了关于同种异体CAR T疗法的临床数据，而Kyverna Therapeutics则推进了自身免疫项目Caribou Biosciences Reports Clinical Data on Allogeneic CAR T Therapies While Kyverna Therapeutics Advances Autoimmune Program\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-05 16:03 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110516052697554e2c&s=b><strong>动脉网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>by GOAI由GOAI生成Share To分享到Caribou Biosciences has released clinical data on its allogeneic CAR T-cell therapies in two cancer indications, while Kyverna Therapeutics is preparing to advance its own CAR...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110516052697554e2c&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110516052697554e2c&s=b","article_id":"2581779056","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110516052697554e2c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2581779056","pubTimestamp":1762329780,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"Caribou presented findings from trials involving its allogeneic CAR T therapies, which use donor-derived cells rather than a patient’s own cells. These therapies were tested in two separate cancer indications, though specific details regarding efficacy or safety outcomes were not disclosed in the report.Caribou公布了其同种异体CAR T疗法的试验结果，该疗法使用捐赠者来源的细胞而非患者自身的细胞。Meanwhile, Kyverna announced plans to move forward with its CAR T program aimed at treating autoimmune conditions. This marks a shift from the traditional focus of CAR T therapy on oncology and represents an effort to expand the technology’s applications into other therapeutic areas. Both companies continue to explore innovative approaches within this rapidly evolving sector of biotechnology..同时，Kyverna 宣布计划推进其旨在治疗自身免疫性疾病的 CAR T 项目。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","LENZ":"Therapeutics","KYTX":"Kyverna Therapeutics","BK4007":"制药","BK4022":"陆运","BK4539":"次新股","BK4230":"旅客陆运","CAR":"安飞士","CRBU":"Caribou Biosciences"},"translate_title":"Caribou Biosciences reports clinical data on allogeneic CAR T therapy, while Kyverna Therapeutics advances autoimmune program Caribou Biosciences Reports Clinical Data on Allogeneic CAR T Therapies While Kyverna Therapeutics Advances Autoimmune Program","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CAR":1.5,"CRBU":1.5,"LENZ":1.5,"KYTX":1.5},"content_text":"by GOAI由GOAI生成Share To分享到Caribou Biosciences has released clinical data on its allogeneic CAR T-cell therapies in two cancer indications, while Kyverna Therapeutics is preparing to advance its own CAR T program targeting autoimmune diseases. The updates highlight ongoing developments in the field of chimeric antigen receptor (CAR) T-cell therapies, which are engineered immune cells designed to target specific diseases..Caribou Biosciences发布了其在两种癌症适应症中的同种异体CAR T细胞疗法的临床数据，而Kyverna Therapeutics正准备推进其针对自身免疫性疾病的CAR T项目。这些更新突显了嵌合抗原受体（CAR）T细胞疗法领域的持续发展，这是一种设计用来靶向特定疾病的工程免疫细胞。Caribou presented findings from trials involving its allogeneic CAR T therapies, which use donor-derived cells rather than a patient’s own cells. These therapies were tested in two separate cancer indications, though specific details regarding efficacy or safety outcomes were not disclosed in the report.Caribou公布了其同种异体CAR T疗法的试验结果，该疗法使用捐赠者来源的细胞而非患者自身的细胞。这些疗法在两种不同的癌症适应症中进行了测试，但报告中并未披露有关疗效或安全性结果的具体细节。Meanwhile, Kyverna announced plans to move forward with its CAR T program aimed at treating autoimmune conditions. This marks a shift from the traditional focus of CAR T therapy on oncology and represents an effort to expand the technology’s applications into other therapeutic areas. Both companies continue to explore innovative approaches within this rapidly evolving sector of biotechnology..同时，Kyverna 宣布计划推进其旨在治疗自身免疫性疾病的 CAR T 项目。这标志着 CAR T 疗法从传统的肿瘤学重点转向了将该技术应用扩展到其他治疗领域。两家公司都在这一快速发展的生物技术领域中继续探索创新方法。Newsflash | Powered by GeneOnline AI新闻快讯 | 由GeneOnline AI提供支持Source: GO-AI-ne1来源：GO-AI-ne1For any suggestion and feedback, please contact us.如有任何建议和反馈，请联系我们。Date: November 4, 2025日期：2025年11月4日Related posts:相关文章：Therapist Network Offers Mental Health Support to Federal Health Workers Amid Reported Stress治疗师网络为面临压力的联邦卫生工作者提供心理健康支持Personalized Medicine Drives Demand for Temperature-Controlled Logistics in Life Sciences Industry个性化医疗推动生命科学行业对温控物流的需求增长Pfizer CEO Albert Bourla Discusses Balancing Drug Innovation and Accessibility in New Era Strategy辉瑞首席执行官阿尔伯特·布尔拉讨论新时代战略中平衡药物创新与可及性的问题New Molecule APT20TTMG Identified as Modulator of U1 snRNP Complex in Glioblastoma Models新分子APT20TTMG被确定为胶质母细胞瘤模型中U1 snRNP复合物的调节剂©www.geneonline.com All rights reserved. Collaborate with us:©www.geneonline.com 版权所有。与我们合作：[email protected]电子邮件地址Author作者GOAIGOAIRelated Post相关文章News Flash新闻快讯Draig Appoints New CEO Amid Leadership Changes in Biotech SectorDraig在生物技术领域领导层变动中任命新首席执行官2025-11-052025年11月5日","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581779056","isCrawlerRequest":true}